The V3 region of the human immunodeficiency virus type 1 envelope protein gp120 constitutes a potential neutralization target, but the oligosaccharide of one conserved N-glycosylation site in this region protects it from neutralizing antibodies. Here, we determined whether N-linked glycans of other gp120 domains were also involved in protection of V3 neutralization epitopes. Two molecular clones of HIV-1, one lacking three N-Iinked glycans of the V1 region (HIV-1(3N/V1)) and another lacking three N-linked glycans of the C2 region (HIV-1(3N/C2)), were created and characterized. gp120 from both mutated viral clones had higher electrophoretic mobilities than gp120 from wild-type virus, confirming loss of N-linked glycans. Wild-type virus and b...
Background: Broadly neutralizing antibodies (bnAbs) directed against the mannose-patch on the HIV en...
The N-linked oligomannose glycans of HIV gp120 are a target for both microbicide and vaccine design....
AbstractA critical component of an effective HIV vaccine will be the induction of broadly neutralizi...
AbstractA conserved N-glycan present within the V3 loop of gp120 modulates the sensitivity to neutra...
The V3 loop of the human immunodeficiency virus (HIV) surface protein, gpl20, constitutes a principa...
The HIV-1 surface glycoprotein, gp120, is made of a rapidly mutating protein core and an extensive c...
A human immunodeficiency virus type 1 (HIV-1) mutant lacking the V1 and V2 variable loops in the gp1...
Human immunodeficiency virus types 1 and 2 (HIV-1 and HIV-2) are the etiological agents of AIDS in h...
<div><p>Understanding the molecular determinants of sensitivity and resistance to neutralizing antib...
The monoclonal antibody (MAb) 2G12 recognizes a cluster of high-mannose oligosaccharides on the huma...
The envelope spike of HIV is one of the most highly N-glycosylated structures found in nature. Howev...
The major target of the neutralizing antibody response to infection by the human immunodeficiency vi...
Thesis (Ph.D.)--University of Washington, 2016-03HIV-1 establishes persistent infection in part due ...
Neutralizing antibodies often recognize regions of viral envelope glycoproteins that play a role in ...
International audienceBroadly neutralizing antibodies (bnAbs) directed against the mannose-patch on ...
Background: Broadly neutralizing antibodies (bnAbs) directed against the mannose-patch on the HIV en...
The N-linked oligomannose glycans of HIV gp120 are a target for both microbicide and vaccine design....
AbstractA critical component of an effective HIV vaccine will be the induction of broadly neutralizi...
AbstractA conserved N-glycan present within the V3 loop of gp120 modulates the sensitivity to neutra...
The V3 loop of the human immunodeficiency virus (HIV) surface protein, gpl20, constitutes a principa...
The HIV-1 surface glycoprotein, gp120, is made of a rapidly mutating protein core and an extensive c...
A human immunodeficiency virus type 1 (HIV-1) mutant lacking the V1 and V2 variable loops in the gp1...
Human immunodeficiency virus types 1 and 2 (HIV-1 and HIV-2) are the etiological agents of AIDS in h...
<div><p>Understanding the molecular determinants of sensitivity and resistance to neutralizing antib...
The monoclonal antibody (MAb) 2G12 recognizes a cluster of high-mannose oligosaccharides on the huma...
The envelope spike of HIV is one of the most highly N-glycosylated structures found in nature. Howev...
The major target of the neutralizing antibody response to infection by the human immunodeficiency vi...
Thesis (Ph.D.)--University of Washington, 2016-03HIV-1 establishes persistent infection in part due ...
Neutralizing antibodies often recognize regions of viral envelope glycoproteins that play a role in ...
International audienceBroadly neutralizing antibodies (bnAbs) directed against the mannose-patch on ...
Background: Broadly neutralizing antibodies (bnAbs) directed against the mannose-patch on the HIV en...
The N-linked oligomannose glycans of HIV gp120 are a target for both microbicide and vaccine design....
AbstractA critical component of an effective HIV vaccine will be the induction of broadly neutralizi...